Libroxar

Buprenorphine, the active ingredient in Libroxar, is an opioid analgesic (partial agonist/antagonist combination) presented as a sublingual tablet for sublingual use. It treats opioid dependence and opioid use disorder in adults. GNH USA supplies Libroxar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Libroxar (buprenorphine/naloxone) is used in the management of opioid dependence, targeting the opioid receptor system.

- Opioid dependence: reduces withdrawal symptoms and cravings during maintenance therapy. - Opioid use disorder: supports long‑term abstinence and prevents relapse. - Opioid detoxification: facilitates safe transition off full‑agonist opioids under medical supervision.

Libroxar may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Headache: mild to moderate head pain. - Nausea: feeling of queasiness. - Constipation: reduced bowel movements. - Sweating: increased perspiration. - Dizziness: light‑headed sensation. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: severe slowing of breathing. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver enzyme elevation: abnormal liver function tests.

Before prescribing Libroxar, clinicians should consider several safety measures.

- Assess dependence severity: evaluate opioid use history before initiating. - Monitor for withdrawal: watch for signs of precipitated withdrawal especially if recent opioid use. - Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol. - Pregnancy and lactation: weigh benefits against potential risks. - Renal or hepatic impairment: adjust therapy as clinically indicated. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Libroxar can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - Other opioids: may precipitate withdrawal or increase toxicity. - CYP3A4 inhibitors (e.g., ketoconazole): raise buprenorphine levels. - Alcohol: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Antidepressants (e.g., SSRIs): monitor for serotonin syndrome. - Antihistamines: may increase sedation. - Anticonvulsants (e.g., carbamazepine): may lower plasma levels.